Last $45.17 USD
Change Today +0.20 / 0.44%
Volume 257.5K
ENTA On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

enanta pharmaceuticals inc (ENTA) Snapshot

Open
$45.25
Previous Close
$44.97
Day High
$45.75
Day Low
$44.76
52 Week High
10/21/14 - $48.49
52 Week Low
11/6/13 - $18.79
Market Cap
839.4M
Average Volume 10 Days
383.8K
EPS TTM
$1.78
Shares Outstanding
18.6M
EX-Date
--
P/E TM
25.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ENANTA PHARMACEUTICALS INC (ENTA)

enanta pharmaceuticals inc (ENTA) Related Bloomberg News

View More Bloomberg News

enanta pharmaceuticals inc (ENTA) Related Businessweek News

No Related Businessweek News Found

enanta pharmaceuticals inc (ENTA) Details

Enanta Pharmaceuticals, Inc., a biotechnology company, is engaged in the development of small molecule drugs for the infectious disease field. Its product portfolio includes ABT-450, a protease inhibitor that is in Phase III clinical trials for the treatment of hepatitis C virus (HCV); ABT-493, a next-generation protease inhibitor for HCV infection; EDP-239, an NS5A inhibitor for HCV infection; Cyclophilin inhibitor, which are in preclinical development stage for HCV infection treatment; and Nucleotide Polymerase inhibitor program for HCV infection. The company also develops Bicyclolide antibiotic products comprising EDP-788 for the treatment of methicillin-resistant Staphylococcus aureus bacteria. It has collaboration and license agreements with Novartis Institutes for BioMedical Research, Inc.; and AbbVie Inc. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

44 Employees
Last Reported Date: 12/18/13
Founded in 1995

enanta pharmaceuticals inc (ENTA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $683.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $420.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $486.4K
Compensation as of Fiscal Year 2013.

enanta pharmaceuticals inc (ENTA) Key Developments

Enanta Pharmaceuticals, Inc. Announces Data Presentations on Regimens Containing ABT-450 or ABT-493

Enanta Pharmaceuticals, Inc. announced that 25 abstracts reporting the results of hepatitis C virus (HCV) treatment regimens containing ABT-450, Enanta's lead protease inhibitor, or ABT-493, Enanta's next-generation protease inhibitor, have been accepted for presentation at The Liver Meeting. Abstracts will be presented the results from AbbVie's investigational treatment regimen combining three direct-acting antivirals (ABT-450/ritonavir, ombitasvir (formerly ABT-267) and dasabuvir, formerly ABT-333) with or without ribavirin (RBV) in patients with genotype 1 (GT1) chronic HCV infection. These abstracts include a phase 2/3 study in patients co-infected with human immunodeficiency virus type-1 (HIV-1) (TURQUOISE-I) and a phase 2 study in liver transplant recipients without cirrhosis (CORAL-I). Additionally, phase 2 data will be presented from investigational studies evaluating the combination of ABT-450/ritonavir and ombitasvir with or without RBV in genotype 4 (GT4) patients (PEARL-I). AbbVie will also be presenting data from its two next-generation HCV compounds, ABT-493 and ABT-530. Results from these studies support the ongoing phase 2b combination studies in patients with HCV.

Enanta Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014

Enanta Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, revenue was $42.051 million against $1.649 million a year ago. Income from operations was $34.895 million against loss from operation of $4.178 million a year ago. Net income before income taxes was $34.931 million against net loss before income taxes of $4.138 million a year ago. Net income attributable to common stockholders was $50.053 million or $2.61 per diluted share against net loss attributable to common stockholders of $4.138 million or $0.23 per diluted share a year ago. For the nine months, revenue was $45.104 million against $30.704 million a year ago. Income from operations was $24.311 million against $13.730 million a year ago. Net income before income taxes was $24.358 million against $14.070 million a year ago. Net income attributable to common stockholders was $39.480 million or $2.06 per diluted share against net loss attributable to common stockholders of $2.126 million or $0.30 per diluted share a year ago.

Enanta Pharmaceuticals' HCV NS5A Inhibitor EDP-239 Advances into Combination Studies with Alisporivir (DEB025)

Enanta Pharmaceuticals, Inc. announced that Novartis has advanced EDP-239, Enanta's NS5A inhibitor for hepatitis C virus (HCV), into drug combination studies with alisporivir (DEB025), a cyclophilin inhibitor being developed by Novartis. These combination studies are part of Enanta's existing collaboration with Novartis for the development of new combination therapies for the treatment of HCV using Enanta's NS5A inhibitors. EDP-239 is a direct-acting anti-viral (DAA) that directly inhibits replication of HCV. Alisporivir (DEB025) blocks HCV replication by targeting proteins in the host cell that are critical to replication of the hepatitis C virus (HCV). As a host-targeting antiviral (HTA), alisporivir (DEB025) is expected to have a high barrier to HCV resistance. It has also demonstrated in vitro anti-HCV activity across multiple HCV genotypes. As the most advanced oral HTA, alisporivir (DEB025), when combined with EDP-239, may be an attractive drug combination for the next-generation of interferon-free HCV therapies. The phase 1 combination study conducted by Novartis is investigating the pharmacokinetics, safety, and tolerability of alisporivir (DEB025) and EDP-239 when co-administered to healthy adult subjects and is scheduled to enroll 42 healthy subjects.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENTA:US $45.17 USD +0.20

ENTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ENTA.
View Industry Companies
 

Industry Analysis

ENTA

Industry Average

Valuation ENTA Industry Range
Price/Earnings 24.3x
Price/Sales 18.0x
Price/Book 5.5x
Price/Cash Flow 24.0x
TEV/Sales 16.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENANTA PHARMACEUTICALS INC, please visit www.enanta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.